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What is already known about the topic 
 Long term abdominal drains (LTAD) are an accepted palliative strategy in 
malignant ascites, but have not been routinely used nor subject to research in 
end stage liver disease (ESLD). 
 Historically, placing LTAD in ESLD for refractory ascites (RA) has been assumed 
to be contraindicated due to concerns regarding infection, acceptability and 
tolerability. 
 There is limited case series data published on LTAD in an ESLD cohort. 
 
What this paper adds 
 Provides preliminary evidence of the safety and effectiveness of palliative 
Rocket LTAD as a novel approach to the palliative management of RA in 
patients with ESLD. 
 Reports the use of prophylactic antibiotics in this setting. 
 
Implications for practice, theory or policy 
 When used as part of a multidisciplinary approach, LTAD may be a safe and 
effective palliative intervention in this cohort. 
 
Abstract 
Background 
Ascites, the commonest complication of cirrhosis, leads to frequent hospitalisations. 
Refractory ascites (RA) confers a median survival of 6 months without liver 
transplantation (LT). In many the management remains palliative (large volume 
paracentesis, LVP). Despite calls for improvement, Palliative and End of Life (EoLC) is 
not yet integrated into end stage liver disease (ESLD). Long-term abdominal drains 
(LTAD) are a palliative strategy in malignant ascites, but not ESLD.  
Case presentation 
A retrospective, single centre, case series review was performed of patients 
undergoing LTAD placement for RA secondary to ESLD at a large teaching hospital 
between August 2011 and March 2013.  
Case management 
Patients with ESLD and RA, where LT was not an option, were considered for LTAD. 
Seven patients underwent successful LTAD insertion after multi-professional 
assessment. 
Case outcome 
Following LTAD, mean hospital attendances reduced to 1 (0-4) from 9 (4-21); with 
none for ascites management. Median survival after LTAD insertion was 29 days (8-
219). The complication rate was low and none life-threatening.  
Conclusions 
Palliative and EoLC needs in ESLD remain under-addressed. Our data suggests LTAD 
may be a safe and effective palliative intervention in ESLD. Prospective randomised 
controlled trials comparing LVP versus LTAD in RA in ESLD are warranted. 
 
Introduction 
Ascites is the most the common complication of cirrhosis, seen in approximately 90% 
of individuals with end stage liver disease (ESLD) (1). It results in frequent, repeated 
hospitalisations due to symptoms such as pain and breathlessness. Unresponsiveness 
to, or intolerance of, diuretics [refractory ascites, (RA)] is a poor prognostic sign in 
ESLD; without liver transplantation (LT) median life expectancy is six months (2, 3). We 
and others have shown less than ten percent of patients with advanced cirrhosis are 
eligible for LT due to comorbidity, alcohol recidivism, substance misuse and 
psychosocial issues (1, 4). Thus in many with RA and ESLD the management remains 
palliative.  
The commonest palliative intervention for RA is frequent large volume paracentesis 
(LVP), on average every 10-14 days (2). To ensure amenability for drainage, patients 
wait until their ascites is tense, with consequent increased symptom severity (5). RA is 
therefore an important determinant of reduced quality of life (QoL) in ESLD (6). 
Individuals with RA often have contraindications for  other interventions such as 
transjugular intrahepatic portosystemic shunts (TIPSS) and the ALFA pump (7, 8, 9). 
Additionally these  are invasive techniques,thus making them  less suitable as palliative 
interventions. 
Long-term abdominal drains (LTAD) are small bore flexible drains tunnelled 
subcutaneously on the abdominal wall, under local anaesthetic, with ultrasound 
guidance (10). Community nurses or if willing, patients/carers, drain  the ascites at 
home dependent on symptoms (e.g. 1-2 Litres, 2-3 times per week). LTAD are an 
accepted palliative strategy in malignant ascites, though to date have not been 
researched in ESLD. 
In the UK, deaths from chronic liver disease have increased 400% since 1970, in sharp 
contrast to other chronic conditions (11). In 2009 over 70% with ESLD died in hospital 
compared to 55% of total deaths (12). There are national calls to improve the overall 
end of life care (EoLC) in ESLD (13). Here we report our early experience with palliative 
LTAD in individuals with RA due to ESLD. 
 
Methods 
A retrospective, single centre, case review was performed of patients who underwent 
LTAD placement for RA secondary to ESLD at Brighton and Sussex University Hospital 
NHS Trust (BSUH) between August 2011 and March 2013.  
This cohort were not LT candidates due to either comorbidity, alcohol recidivism, 
substance misuse and or psychosocial factors; often in combination. Suitability for 
LTAD was assessed by a multi-disciplinary group including Hepatologists and Palliative 
Medicine physicians. Prior spontaneous bacterial peritonitis (SBP) did not 
automatically contraindicate LTAD insertion. LTAD was discussed with patients and 
family (if present) and all patients gave written consent prior to insertion. 
Two LTADs were available in England at the time: PleurX® (UK Medical Ltd, 
Basingstoke, UK) and Rocket Medical (Watford, UK). Rocket Medical LTAD were utilised 
due to experience amongst clinicians siting the LTAD and community nursing teams 
providing ongoing support. 
LTADs were inserted under ultrasound guidance by JM and MA as per ŵaŶufactuƌeƌ’s 
instructions (10). Local hospital policy regarding use of blood/clotting products was 
followed, (platelet count < 50x109 and or INR > 2), however, none were required. Data 
was collected retrospectively from patient records. Following review of preliminary 
data from the first five cases, prophylactic norfloxacin/ciprofloxacin use post LTAD 
insertion was initiated. No patient had prior (SBP). 
As of April 2016, all but one patient are deceased, hence obtaining consent for 
publication from next of kin was considered inappropriate; the surviving patient gave 
written consent. 
 
Results 
During the study period, eight patients were deemed appropriate for LTAD; seven 
underwent successful insertion, one dying soon after assessment. All patients had 
clinical, biochemical and radiological evidence of cirrhosis and LT was contraindicated 
due to either comorbidity and or alcohol recidivism (Table 1). 
This was an elderly, predominantly female, cohort, median age at insertion 71 years 
(55-80); non-alcoholic fatty liver disease (NAFLD) being the dominant aetiology of ESLD 
(57%) (Table 1).  Five (71%) had Child Pugh B and two Child Pugh C disease (29%).  --- 
had had  SBP prior to LTAD and how long prior to LTAD insertion. Were these on 
antibiotic prophylaxis All patients had at least one comorbidity, the commonest being 
diabetes mellitus (DM) (71%). 
Of the seven cases, one remained on diuretics at the time of LTAD insertion. In the 
remaining six, diuretics had been stopped historically due to intolerance 
(hyponatraemia and or renal dysfunction).  
In the six months prior to LTAD insertion the median number of LVP episodes was 7 (4-
17). Following the intervention, GI related hospital attendance reduced from a median 
of 9 (4-21) to 1 (0-4), however none of these attendances were for management of 
ascites or LVP (Table 1). 
Complications 
Subsequent to LTAD insertion one patient developed drain site cellulitis, treated 
successfully with antibiotics. A second developed cellulitis requiring LTAD removal 
(drain duration 219 days), however, LTAD was ƌeiŶstated at patieŶt’s ƌeƋuest oŶce 
cellulitis had resolved (see below); a third developed hepatic encephalopathy (HE), the 
cause unclear. Ascitic fluid culture obtained from the LTAD grew Pseudomonas 
aeruginosa and Corynebacterium striatum, therefore must be interpreted with 
caution. There was no improvement with empirical antibiotic treatment, the patient 
subsequently developed gastrointestinal bleeding and was managed palliatively with 
fast-track home for EoLC. 
Median survival following LTAD insertion was 29 days (8-219). Six patients died during 
follow up, mortality being liver related in all. The place of death in four cases was 
recorded as in hospital, one in their own home and one in a care home. The single 
surviving patient had a second LTAD sited, at their request, after removal of the first 
due to cellulitis (see above). The second LTAD remains in situ (436 days at last follow 
up). 
 
Discussion 
This is a single centre experience of palliative Rocket Medical LTAD in RA due to ESLD. 
Despite the small sample size, our data suggest that, when used as part of a 
multidisciplinary approach, LTAD may be a safe and effective palliative intervention in 
this cohort. Technical success was 100% with no further LVP requirement. Median 
survival following LTAD insertion was 29 days, however, patients were referred late in 
their disease trajectory having already undergone multiple LVPs; resulting in less scope 
for intervention earlier on a palliative pathway. Complications observed with LTAD 
were not life-threatening and in none did the LTAD conclusively and directly contribute 
to death; this being liver related in all.  
Patients with ESLD have complex and challenging medical needs related to a 
fluctuating disease trajectory (severe near fatal exacerbations or decompensations), 
ongoing alcohol use, mental health issues and social isolation/stigmatisation. 
Additional factors include younger age (90% of patients are < 70 years and 1:10 are < 
40 years), hence may not have engaged with health services (12). Finally is the 
consistent lack of public, as well as healthcare professional, awareness that ESLD is a 
life limiting condition (12). 
LTAD are an accepted palliative strategy in malignant ascites. A NICE technology 
appraisal (review of nine studies, 180 patients, all using PleurX® drains) lend credence 
to LTAD within this setting with low complication rates (device related infections 
5.8%), 100% technical success and improved symptom control (14).  Traditionally, use 
of LTAD in ESLD has been hampered by concerns regarding infection, acceptability and 
tolerability. This is despite the potential advantages (avoidance of frequent 
hospitalisations, some LVP associated complications, spending the majority of 
remaining life at home, improved QoL and possible economic benefits).  
There is thus limited published data on LTAD in an ESLD cohort with only small case 
series (total 66 patients) (15, 16, 17, 18) all using PleurX® drains. Catheter related 
infections were low (7/66, all being bacterial peritonitis) with LTAD remaining in situ 
for up to four months. However prophylactic antibiotics were only used in one study 
(15). In another case series of 46 patients, (nine with portal hypertension), Semadeni 
et al reported 98% technical success rate, 9% bacterial peritonitis, with a mean 
catheter (PleurX®) and patient survival of 65 and 91 days respectively; the best survival 
seen in those with portal hypertension (111 and 192 days respectively) (19).  
Since this was an EoL cohort our main emphasis was on  improving QoL. Therefore 
those with prior SBP were not automatically excluded from LTAD insertion. The 
reasons why we did not conclusively  observe SBP post LTAD insertion are unclear but 
could include the small sample size and short follow up.  Additionally, earlier studies in 
malignant ascites have shown that risk of peritonitis is significantly lower with 
tunnelled vs. non tunnelled drains (4.4% vs 34.2%)  (Fleming et al, ref at the end of 
manuscript). Nonetheless we are cognisant of the potential for SBP in ESLD and hence 
introduced antibiotic prophylaxis after the first five patients. 
 
Encouraged by this and our own data, our group has obtained National Institute for 
Health Research (NIHR) funding for a prospective feasibility randomised controlled trial 
comparing palliative Rocket LTAD versus LVP in ESLD (REDUCe Study, ISRCTN 
30697116). Embedded are assessments of whether an ESLD cohort can be managed 
outside of secondary care, a concurrent qualitative study and Qol and health 
economics assessment. 
In conclusion, we provide preliminary evidence of the safety and effectiveness of 
palliative Rocket LTAD in the management of patients with RA due to ESLD. EoLC in 
ESLD remains an unmet need and will mandate a paradigm shift in attitudes and 
practice both amongst healthcare professionals and wider society. 
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Table 1. Demographic, clinical and hospital attendance data. Data are presented as 
median and range. 
Age (years) 71 (55-80) 
Gender  
 Female 4 (57%) 
 Male 3 (43%) 
Aetiology  
 NAFLD 3 (43%) 
 ARLD 2 (29%) 
 Cryptogenic 1 (14%) 
 NAFLD/ARLD 1 (14%) 
Co-morbidities  
 Diabetes 5 (71%) 
 IHD 4 (57%) 
 CKD 3 (43%) 
 Others* 
 
Laboratory results  
(reference ranges) 
Median (range) 
Sodium (136-145 mmol/L) 131 (119-142) 
Creatinine (62-106 umol/L) 134 (125-188) 
eGFR (>60 mL/min) 33 (32-43) 
Albumin (35-52 g/L) 32 (22-43) 
Bilirubin (0-21 umol/L) 19 (7-32) 
INR (0.8-1.2) 1.3 (1.2-1.6) 
ALT (0-41 iu/L) 16 (12-73) 
ALP (40-129 iu/L) 139 (80-251) 
Child Pugh Score 
 
9 (7-11) 
Model for End Stage Liver Disease 
(MELD) score 
16 (12-18) 
UK End Stage Liver Disease 
(UKELD) score 
55 (46-64) 
 Six months prior to 
LTAD insertion 
Following LTAD insertion 
Hepatology related hospital 
attendances 
9 (4-21) 1 (0-4) (all cause hospital 
attendance) 
Hepatology related outpatient 
clinic attendances 
2 (0-3) 0 
Hepatology related inpatient 
admissions 
5 (1-11) 1.5 (0-4) 
Day case large volume 
paracentesis attendances 
2 (1-7) 0 
Large volume paracentesis 
episodes (both inpatient and  day 
case) 
7 (4-17) 0 
*others = Chronic obstructive pulmonary disease, hypertension, stroke, congestive cardiac 
failure, peripheral vascular disease, atrial fibrillation, previous bowel cancer.  
 
 
 
 
 
 
 
 
 
  
 
 
 
